<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Birgitta Kullgren | HOPO Therapeutics</title>
    <link>/authors/birgitta-kullgren/</link>
      <atom:link href="/authors/birgitta-kullgren/index.xml" rel="self" type="application/rss+xml" />
    <description>Birgitta Kullgren</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>Â© 2020 HOPO Therapeutics, Inc.</copyright><lastBuildDate>Sat, 01 Apr 2017 00:00:00 +0000</lastBuildDate>
    <image>
      <url>img/map[gravatar:%!s(bool=false) shape:square]</url>
      <title>Birgitta Kullgren</title>
      <link>/authors/birgitta-kullgren/</link>
    </image>
    
    <item>
      <title>From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents</title>
      <link>/publication/an-early-2017/</link>
      <pubDate>Sat, 01 Apr 2017 00:00:00 +0000</pubDate>
      <guid>/publication/an-early-2017/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimen.</title>
      <link>/publication/bunin-dose-dependent-2013/</link>
      <pubDate>Tue, 01 Jan 2013 00:00:00 +0000</pubDate>
      <guid>/publication/bunin-dose-dependent-2013/</guid>
      <description></description>
    </item>
    
    <item>
      <title>3,4,3-LI(1,2-HOPO): In vitro formation of highly stable lanthanide complexes translates into efficacious in vivo europium decorporation</title>
      <link>/publication/sturzbecher-hoehne-343-li-12-hopo-2011/</link>
      <pubDate>Sat, 01 Jan 2011 00:00:00 +0000</pubDate>
      <guid>/publication/sturzbecher-hoehne-343-li-12-hopo-2011/</guid>
      <description></description>
    </item>
    
    <item>
      <title>Biomimetic Actinide Chelators: An Update on the Preclinical Development of the Orally Active Hydroxypyridonate Decorporation Agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO)</title>
      <link>/publication/abergel-biomimetic-2010/</link>
      <pubDate>Wed, 01 Sep 2010 00:00:00 +0000</pubDate>
      <guid>/publication/abergel-biomimetic-2010/</guid>
      <description></description>
    </item>
    
  </channel>
</rss>
